Neratinib

157 interactions 330 cited references

Also sold as: Nerlynx Nerlynx®

About Neratinib

Neratinib is used to treat a certain type of hormone receptor-positive breast cancer (breast cancer that depends on hormones such as estrogen to grow) in adults after treatment with trastuzumab (Herceptin) and other medications. Neratinib is used along with capecitabine (Xeloda) to treat a certain type of advanced horm… Read the full Neratinib drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Rubella Virus Vaccine, Live Levoketoconazole Mifepristone Measles Virus Vaccine, Live Ensitrelvir Mumps Virus Vaccine, Live

12 Contraindicated 139 Major 6 Moderate

All (157) Contraindicated (12) Major (139) Moderate (6)

Major

Neratinib Indinavir Increased neratinib exposure and risk of toxicity Details Neratinib Influenza Virus Vaccine, Live An increased risk of infection by the live vaccine Details Neratinib Itraconazole Sporanox Increased neratinib exposure and risk of toxicity Details Neratinib Ketoconazole Extina Increased neratinib exposure and risk of toxicity Details Neratinib Lanreotide Altered exposure to CYP3A4 substrate Details Neratinib Lazertinib Lazcluze Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Neratinib Letermovir Prevymis Increased CYP3A substrate exposure Details Neratinib Lonafarnib Zokinvy Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A substrate with NTI-related serious or life-threatening... Details Neratinib Lopinavir Increased neratinib exposure and risk of toxicity Details Neratinib Lorlatinib Lorbrena Decreased exposure of neratinib and risk of reduced efficacy Details Neratinib Lumacaftor Decreased exposure of neratinib and active metabolites and risk of reduced efficacy Details Neratinib Magaldrate Decreased neratinib exposure Details Neratinib Magnesium Carbonate Decreased neratinib exposure Details Neratinib Magnesium Hydroxide Almacone® (containing Aluminum Hydroxide, Magnesium Hydroxide, Simethicone) Decreased neratinib exposure Details Neratinib Magnesium Oxide Mag-Ox 400 Decreased neratinib exposure Details Neratinib Magnesium Trisilicate Decreased neratinib exposure Details Neratinib Mavorixafor Xolremdi Increased mavorixafor exposure, increased CYP3A4 substrate with NTI exposure, increased risk of CYP3A4 with NTI-related adverse ef... Details Neratinib Mitotane Lysodren Decreased exposure of neratinib and active metabolites and risk of reduced efficacy Details Neratinib Mobocertinib Exkivity Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Neratinib Modafinil Provigil Decreased exposure of neratinib and risk of reduced efficacy Details Neratinib Morphine Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Neratinib Morphine Sulfate Liposome Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Neratinib Nafcillin Decreased exposure of neratinib and risk of reduced efficacy Details Neratinib Nefazodone Increased neratinib exposure and risk of toxicity Details Neratinib Nelfinavir Viracept Increased neratinib exposure and risk of toxicity Details Neratinib Netupitant Increased exposure of CYP3A4 substrate Details Neratinib Nirmatrelvir Increased neratinib exposure and risk of toxicity Details Neratinib Nirogacestat Ogsiveo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Neratinib Nizatidine Axid® Decreased neratinib solubility, absorption, and exposure Details Neratinib Octreotide Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Neratinib Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Neratinib Pacritinib Vonjo® Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Neratinib Palbociclib Ibrance Increased exposure to CYP3A substrates with a narrow therapeutic index Details Neratinib Pantoprazole Protonix Decreased neratinib solubility, absorption, and exposure Details Neratinib Phenobarbital Fidoquel Decreased exposure of neratinib and risk of reduced efficacy Details Neratinib Phenytoin Dilantin Decreased exposure of neratinib and active metabolites and risk of reduced efficacy Details Neratinib Posaconazole Noxafil Increased neratinib exposure, an increased risk of neratinib toxicity and an increased posaconazole exposure Details Neratinib Primidone Mysoline Decreased exposure of neratinib and risk of reduced efficacy Details Neratinib Rabeprazole Aciphex Decreased neratinib solubility, absorption, and exposure Details Neratinib Ranitidine Decreased neratinib solubility, absorption, and exposure Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.